10/516079

```
FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006

=> index biosci
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s chlorotoxin
          3   FILE ADISINSIGHT
          5   FILE AGRICOLA
          1   FILE ANABSTR
         32   FILE BIOSIS
          3   FILE BIOTECHABS
          3   FILE BIOTECHDS
          8   FILE BIOTECHNO
         11   FILE CABA
         41   FILE CAPLUS
          1   FILE CEABA-VTB
          8   FILE CIN
          2   FILE DDFU
        235   FILE DGENE
          2   FILE DISSABS
          2   FILE DRUGU
         28   FILE EMBASE
         22   FILE ESBIOBASE
          1   FILE GENBANK
         13   FILE IFIPAT
          9   FILE IMSDRUGNEWS
          5   FILE IMSRESEARCH
         13   FILE LIFESCI
         31   FILE MEDLINE
         17   FILE PASCAL
          5   FILE PHAR
          5   FILE PHIN
         29   FILE PROMT
         38   FILE SCISEARCH
         68   FILE TOXCENTER
         38   FILE USPATFULL
          7   FILE USPAT2
  64 FILES SEARCHED...
         11   FILE WPIDS
         11   FILE WPINDEX

  33 FILES HAVE ONE OR MORE ANSWERS,   68 FILES SEARCHED IN STNINDEX

L1   QUE CHLOROTOXIN

=> s l1 and chemother?
          1   FILE ADISINSIGHT
          1   FILE BIOTECHNO
          2   FILE CAPLUS
        129   FILE DGENE
          2   FILE EMBASE
          2   FILE ESBIOBASE
          1   FILE IFIPAT
          1   FILE IMSDRUGNEWS
          1   FILE IMSRESEARCH
          1   FILE MEDLINE
  48 FILES SEARCHED...
          2   FILE PHAR
          1   FILE PHIN
         11   FILE PROMT
          3   FILE TOXCENTER
         16   FILE USPATFULL
          4   FILE USPAT2
          2   FILE WPIDS
          2   FILE WPINDEX

  18 FILES HAVE ONE OR MORE ANSWERS,   68 FILES SEARCHED IN STNINDEX

L2   QUE L1 AND CHEMOTHER?

=> b dgene caplus biotechno embase esbiobase ifipat medline promt toxcenter uspatfull uspat2
wpids wpindex
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.44       2.65

FILE 'DGENE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 03:12:00 ON 09 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'MEDLINE' ENTERED AT 03:12:00 ON 09 JUN 2006

FILE 'PROMT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s l2
L3          174 L2

=> dup remo
ENTER L# LIST OR (END):l3
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4           163 DUP REMO L3 (11 DUPLICATES REMOVED)
```

=> s l4 and (bcnu or cisplatin or gemcitabine or hydroxyurea or paclitaxel or temozomide or topotecan or fluorouracil or vincristine or vinblastine or procarbazine or dacarbazine or altretamine)
   8 FILES SEARCHED...
L5   9 L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR PACLITAXEL OR TEMOZOMIDE OR TOPOTECAN OR FLUOROURACIL OR VINCRISTINE OR VINBLASTINE OR PROCARBAZINE OR DACARBAZINE OR ALTRETAMINE)

=> s l4 and (ciplatin or methotrexate or mercaptopurine or thioguanine or fludarabine or cladribine or pentostatin or cytarabine or azacitidine or vinblastine or etoposide or teniposide or irinotecan)
L6   13 L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGUANINE OR FLUDARABINE OR CLADRIBINE OR PENTOSTATIN OR CYTARABINE OR AZACITIDINE OR VINBLASTINE OR ETOPOSIDE OR TENIPOSIDE OR IRINOTECAN)

=> s l4 and (docetaxel or doxorubicin or daunorubicin or dactinomycin or idarubicin or plicamycin or mitomycin or bleomycin or tamoxifen or flutamide or leuprolide or goserelin or aminoglutethimide)
L7   13 L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOMYCIN OR IDARUBICIN OR PLICAMYCIN OR MITOMYCIN OR BLEOMYCIN OR TAMOXIFEN OR FLUTAMIDE OR LEUPROLIDE OR GOSERELIN OR AMINOGLUTETHIMIDE)

=> s l4 and (anastrozole or amsacrine or asparaginase or mitoxantrone or mitotane or amifostine)
L8   7 L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANTRONE OR MITOTANE OR AMIFOSTINE)

=> s l5 and l6 and l7 and l8
L9   6 L5 AND L6 AND L7 AND L8

=> d l9 1-6 bib abs

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1154420 CAPLUS
DN 143:432633
TI Use of **chlorotoxin** in diagnosis and treatment of myeloid and lymphoid cell cancers
IN Alvarez, Vernon L.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 52 pp.
    CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099774	A2	20051027	WO 2005-US11523	20050406
	WO 2005099774	A3	20060323		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2004-559433P	P	20040406		

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with **chlorotoxin** and/or derivs., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The **chlorotoxin** may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the **chlorotoxin** may be conjugated to a cytotoxic agent or **chemotherapeutic** agent.

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971907 CAPLUS
DN 140:23219
TI Combination **chemotherapy** with **chlorotoxin** for treating cancer
IN Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 100 pp.
    CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101474	A1	20031211	WO 2003-US17410	20030602
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487425	AA	20031211	CA 2003-2487425	20030602
	AU 2003240496	A1	20031219	AU 2003-240496	20030602
	EP 1553962	A1	20050720	EP 2003-731504	20030602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005537234	T2	20051208	JP 2004-508829	20030602
	US 2006088899	A1	20060427	US 2005-516079	20051102
PRAI	US 2002-384171P	P	20020531		
	US 2002-406033P	P	20020827		
	WO 2003-US17410	W	20030602		

AB This invention includes compns. and methods for combination **chemotherapy**, particularly involving at least one **chemotherapeutic** agent used in combination with **chlorotoxin** or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled **chlorotoxin** or **chlorotoxin** derivative are also claimed.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
           ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 IFIPAT COPYRIGHT 2006 IFI on STN
AN 11139883 IFIPAT;IFIUDB;IFICDB
TI COMBINATION **CHEMOTHERAPY** WITH **CHLOROTOXIN**
INF Alvarez; Vernon L, Birmingham, AL, US
     Gonda; Matthew A, Birmingham, AL, US
     Grimes; Carol A, Birmingham, AL, US
IN Alvarez Vernon L; Gonda Matthew A; Grimes Carol A
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
PI US 2006088899 A1 20060427
AI US 2003-516079 20030602
    WO 2003-US17410 20030602
                     20051102 PCT 371 date
                     20051102 PCT 102(e) date
PRAI US 2002-384171P 20020531 (Provisional)
      US 2002-406033P 20020827 (Provisional)
FI US 2006088899 20060427

DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
PARN This application claims the benefit of U.S. Provisional Application 60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by reference in their entirety.
CLMN 17
OF 6 IFIPAT COPYRIGHT 2006 IFI on STN
AB This invention includes compositions and methods for combination **chemotherapy**, particularly involving at least one **chemotherapeutic** agent used in combination with **chlorotoxin** or a derivative thereof.
CLMN 17

L9 ANSWER 4 OF 6 USPATFULL on STN
AN 2005:234233 USPATFULL
TI PI-3 kinase inhibitor prodrugs
IN Garlich, Joseph R., Westfield, IN, UNITED STATES
Durden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, GA, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2005203173 A1 20050915
AI US 2005-111201 A1 20050420 (11)
RLI Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE 200, FALLS CHURCH, VA, 22042-2924, US
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 6 USPATFULL on STN
AN 2005:105793 USPATFULL
TI Therapy via targeted delivery of nanoscale particles
IN Ivkov, Robert, Marblehead, MA, UNITED STATES
Daum, Wolfgang, Groton, MA, UNITED STATES
Foreman, Allan, Epping, NH, UNITED STATES
Gwost, Douglas, Shoreview, MN, UNITED STATES
PA Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)
PI US 2005090732 A1 20050428
AI US 2003-696399 A1 20031028 (10)
DT Utility
FS APPLICATION
LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET, PITTSBURGH, PA, 15219, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2898
AB Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

L9 ANSWER 6 OF 6 USPATFULL on STN
AN 2004:307955 USPATFULL
TI PI-3 kinase inhibitor prodrugs
IN Garlich, Joseph R., Westfield, IN, UNITED STATES
Durden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2004242631 A1 20041202
US 6949537 B2 20050927
AI US 2004-818145 A1 20040405 (10)
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34, 1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

SEA CHLOROTOXIN

3	FILE ADISINSIGHT
5	FILE AGRICOLA
1	FILE ANABSTR
32	FILE BIOSIS
3	FILE BIOTECHABS
3	FILE BIOTECHDS
8	FILE BIOTECHNO
11	FILE CABA
41	FILE CAPLUS
1	FILE CEABA-VTB
8	FILE CIN
2	FILE DDFU
235	FILE DGENE
2	FILE DISSABS
2	FILE DRUGU
28	FILE EMBASE
22	FILE ESBIOBASE
1	FILE GENBANK
13	FILE IFIPAT
9	FILE IMSDRUGNEWS
5	FILE IMSRESEARCH

```
            13   FILE LIFESCI
            31   FILE MEDLINE
            17   FILE PASCAL
             5   FILE PHAR
             5   FILE PHIN
            29   FILE PROMT
            38   FILE SCISEARCH
            68   FILE TOXCENTER
            38   FILE USPATFULL
             7   FILE USPAT2
            11   FILE WPIDS
            11   FILE WPINDEX
L1            QUE CHLOROTOXIN
              ---------
              SEA L1 AND CHEMOTHER?
              ---------
             1   FILE ADISINSIGHT
             1   FILE BIOTECHNO
             2   FILE CAPLUS
           129   FILE DGENE
             2   FILE EMBASE
             2   FILE ESBIOBASE
             1   FILE IFIPAT
             1   FILE IMSDRUGNEWS
             1   FILE IMSRESEARCH
             1   FILE MEDLINE
             2   FILE PHAR
             1   FILE PHIN
            11   FILE PROMT
             3   FILE TOXCENTER
            16   FILE USPATFULL
             4   FILE USPAT2
             2   FILE WPIDS
             2   FILE WPINDEX
L2            QUE L1 AND CHEMOTHER?
              ---------

    FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOBASE, IFIPAT, MEDLINE,
    PROMT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09
    JUN 2006
L3          174 S L2
L4          163 DUP REMO L3 (11 DUPLICATES REMOVED)
L5            9 S L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
L6           13 S L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGU
L7           13 S L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM
L8            7 S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANT
L9            6 S L5 AND L6 AND L7 AND L8

=> d l5 1-9 bib abs

L5   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1154420  CAPLUS
DN   143:432633
TI   Use of chlorotoxin in diagnosis and treatment of myeloid and
     lymphoid cell cancers
IN   Alvarez, Vernon L.; Gonda, Matthew A.
PA   Transmolecular, Inc., USA
SO   PCT Int. Appl., 52 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2005099774        A2    20051027    WO 2005-US11523        20050406
     WO 2005099774        A3    20060323
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
             SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
             ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI US 2004-559433P      P     20040406
AB   Disclosed is a method of diagnosing and treating myeloproliferative or
     lymphoproliferative cell disorders, such as cancer, with
     chlorotoxin and/or derivs., analogs or fragments thereof, which
     are effective to bind to an inhibit abnormal myeloid or lymphoid cell
     growth.  The chlorotoxin may be conjugated to a second protein,
     e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific
     epitope, or a stabilizing protein such as human serum albumin.
     Alternatively, the chlorotoxin may be conjugated to a cytotoxic
     agent or chemotherapeutic agent.

L5   ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2003:971907  CAPLUS
DN   140:23219
TI   Combination chemotherapy with chlorotoxin for treating
     cancer
IN   Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.
PA   Transmolecular, Inc., USA
SO   PCT Int. Appl., 100 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2003101474        A1    20031211    WO 2003-US17410        20030602
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2487425            AA    20031211    CA 2003-2487425        20030602
     AU 2003240496         A1    20031219    AU 2003-240496         20030602
     EP 1553962            A1    20050720    EP 2003-731504         20030602
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005537234         T2    20051208    JP 2004-508829         20030602
     US 2006088899         A1    20060427    US 2005-516079         20051102
PRAI US 2002-384171P      P     20020531
     US 2002-406033P      P     20020827
     WO 2003-US17410      W     20030602
AB   This invention includes compns. and methods for combination
     chemotherapy, particularly involving at least one
     chemotherapeutic agent used in combination with
     chlorotoxin or a derivative thereof.  A method for detecting the
     presence of cancer in a patient comprising administering a detectable amount
     of labeled chlorotoxin or chlorotoxin derivative are also
     claimed.
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 3 OF 9  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
AN   2002227256  EMBASE
TI   Orathecin is active in pancreatic cancer patients.
```

SO Expert Review of Anticancer Therapy, (2002) Vol. 2, No. 2, pp. 137-140. .
ISSN: 1473-7140 CODEN: ERATBJ
CY United Kingdom
DT Journal; Note
FS 016 Cancer
027 Biophysics, Bioengineering and Medical Instrumentation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LA English
ED Entered STN: 11 Jul 2002
Last Updated on STN: 11 Jul 2002
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L5 ANSWER 4 OF 9 IFIPAT COPYRIGHT 2006 IFI on STN
AN 11139883 IFIPAT;IFIUDB;IFICDB
TI COMBINATION **CHEMOTHERAPY** WITH **CHLOROTOXIN**
INF Alvarez; Vernon L, Birmingham, AL, US
Gonda; Matthew A, Birmingham, AL, US
Grimes; Carol A, Birmingham, AL, US
IN Alvarez Vernon L; Gonda Matthew A; Grimes Carol A
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
PI US 2006088899 A1 20060427
AI US 2003-516079 20030602
WO 2003-US17410 20030602
20051102 PCT 371 date
20051102 PCT 102(e) date
PRAI US 2002-384171P 20020531 (Provisional)
US 2002-406033P 20020827 (Provisional)
FI US 2006088899 20060427
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
PARN This application claims the benefit of U.S. Provisional Application 60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by reference in their entirety.
CLMN 17
OF 9 IFIPAT COPYRIGHT 2006 IFI on STN
AB This invention includes compositions and methods for combination **chemotherapy**, particularly involving at least one **chemotherapeutic** agent used in combination with **chlorotoxin** or a derivative thereof.
CLMN 17

L5 ANSWER 5 OF 9 PROMT COPYRIGHT 2006 Gale Group on STN

AN 2000:824983 PROMT
TI OTHER NEWS TO NOTE.
SO BIOWORLD Today, (22 Sep 2000) Vol. 11, No. 184.
PB American Health Consultants, Inc.
DT Newsletter
LA English
WC 1452
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB Axys Pharmaceuticals Inc., of South San Francisco, said it agreed to sell $26 million aggregate principal amount of 8 percent senior secured convertible notes maturing on Oct. 1, 2004. Axys previously announced its intention to sell up to $20 million of fixed rate convertible notes. Diaz & Altschul Capital LLC. served as placement agent for the transaction. (See BioWorld Today, Sept. 19, 2000, p. 1.)
THIS IS THE FULL TEXT: COPYRIGHT 2000 American Health Consultants, Inc.

Subscription: $1350.00 per year. Published daily (5 times a week).

L5 ANSWER 6 OF 9 USPATFULL on STN
AN 2005:234233 USPATFULL
TI PI-3 kinase inhibitor prodrugs
IN Garlich, Joseph R., Westfield, IN, UNITED STATES
Durden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, GA, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2005203173 A1 20050915
AI US 2005-111201 A1 20050420 (11)
RLI Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE 200, FALLS CHURCH, VA, 22042-2924, US
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL on STN
AN 2005:105793 USPATFULL
TI Therapy via targeted delivery of nanoscale particles
IN Ivkov, Robert, Marblehead, MA, UNITED STATES
Daum, Wolfgang, Groton, MA, UNITED STATES
Foreman, Allan, Epping, NH, UNITED STATES
Gwost, Douglas, Shoreview, MN, UNITED STATES
PA Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)
PI US 2005090732 A1 20050428
AI US 2003-696399 A1 20031028 (10)
DT Utility
FS APPLICATION
LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET, PITTSBURGH, PA, 15219, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2898
AB Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

L5 ANSWER 8 OF 9 USPATFULL on STN
AN 2004:307955 USPATFULL
TI PI-3 kinase inhibitor prodrugs
IN Garlich, Joseph R., Westfield, IN, UNITED STATES
Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2004242631 A1 20041202
US 6949537 B2 20050927
AI US 2004-818145 A1 20040405 (10)
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34, 1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 USPATFULL on STN
AN 2004:197463 USPATFULL
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES
Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES
Dyakonov, Tatyana A., Durham, NC, UNITED STATES
PI US 2004152769 A1 20040805
AI US 2003-703647 A1 20031107 (10)
PRAI US 2002-424796P 20021109 (60)
US 2003-483676P 20030630 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR', and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thioimide, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonimide group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated form the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intraveneous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

SEA CHLOROTOXIN
---
3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHABS
3 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISSABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESBIOBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMSDRUGNEWS
5 FILE IMSRESEARCH
13 FILE LIFESCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PROMT
38 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPATFULL
7 FILE USPAT2
11 FILE WPIDS
11 FILE WPINDEX
L1 QUE CHLOROTOXIN

SEA L1 AND CHEMOTHER?
---
1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE ESBIOBASE
1 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH
1 FILE MEDLINE
2 FILE PHAR
1 FILE PHIN
11 FILE PROMT
3 FILE TOXCENTER
16 FILE USPATFULL
4 FILE USPAT2
2 FILE WPIDS
2 FILE WPINDEX
L2 QUE L1 AND CHEMOTHER?

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOBASE, IFIPAT, MEDLINE, PROMT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09 JUN 2006
L3 174 S L2
L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)
L5 9 S L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
L6 13 S L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGU
L7 13 S L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM

```
L8            7 S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANT
L9            6 S L5 AND L6 AND L7 AND L8

=> d l6 1-13 bib abs

L6   ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1154420  CAPLUS
DN   143:432633
TI   Use of chlorotoxin in diagnosis and treatment of myeloid and
     lymphoid cell cancers
IN   Alvarez, Vernon L.; Gonda, Matthew A.
PA   Transmolecular, Inc., USA
SO   PCT Int. Appl., 52 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2005099774        A2    20051027    WO 2005-US11523         20050406
     WO 2005099774        A3    20060323
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
             SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
             ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI US 2004-559433P      P     20040406
AB   Disclosed is a method of diagnosing and treating myeloproliferative or
     lymphoproliferative cell disorders, such as cancer, with
     chlorotoxin and/or derivs., analogs or fragments thereof, which
     are effective to bind to an inhibit abnormal myeloid or lymphoid cell
     growth.  The chlorotoxin may be conjugated to a second protein,
     e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific
     epitope, or a stabilizing protein such as human serum albumin.
     Alternatively, the chlorotoxin may be conjugated to a cytotoxic
     agent or chemotherapeutic agent.

L6   ANSWER 2 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2003:971907  CAPLUS
DN   140:23219
TI   Combination chemotherapy with chlorotoxin for treating
     cancer
IN   Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.
PA   Transmolecular, Inc., USA
SO   PCT Int. Appl., 100 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2003101474        A1    20031211    WO 2003-US17410         20030602
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2487425            AA    20031211    CA 2003-2487425         20030602
     AU 2003240496         A1    20031219    AU 2003-240496          20030602
     EP 1553962            A1    20050720    EP 2003-731504          20030602
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005537234         T2    20051208    JP 2004-508829          20030602
     US 2006088899         A1    20060427    US 2005-516079          20051102
PRAI US 2002-384171P       P     20020531
     US 2002-406033P       P     20020827
     WO 2003-US17410       W     20030602
AB   This invention includes compns. and methods for combination
     chemotherapy, particularly involving at least one
     chemotherapeutic agent used in combination with
     chlorotoxin or a derivative thereof.  A method for detecting the
     presence of cancer in a patient comprising administering a detectable amount
     of labeled chlorotoxin or chlorotoxin derivative are also
     claimed.
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 3 OF 13  IFIPAT  COPYRIGHT 2006 IFI on STN
AN    11139883  IFIPAT;IFIUDB;IFICDB
TI    COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN
INF   Alvarez; Vernon L, Birmingham, AL, US
      Gonda; Matthew A, Birmingham, AL, US
      Grimes; Carol A, Birmingham, AL, US
IN    Alvarez Vernon L; Gonda Matthew A; Grimes Carol A
PAF   Unassigned
PA    Unassigned Or Assigned To Individual (68000)
AG    MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,
      20004, US
PI    US 2006088899   A1  20060427
AI    US 2003-516079      20030602
      WO 2003-US17410     20030602
                          20051102  PCT 371 date
                          20051102  PCT 102(e) date
PRAI  US 2002-384171P     20020531 (Provisional)
      US 2002-406033P     20020827 (Provisional)
FI    US 2006088899       20060427
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
PARN  This application claims the benefit of U.S. Provisional Application
      60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application
      60/384,171 (filed May 31, 2002) both of which are hereby incorporated by
      reference in their entirety.
CLMN  17
 OF 13  IFIPAT  COPYRIGHT 2006 IFI on STN
AB    This invention includes compositions and methods for combination
      chemotherapy, particularly involving at least one
      chemotherapeutic agent used in combination with
      chlorotoxin or a derivative thereof.
CLMN  17

L6   ANSWER 4 OF 13  USPATFULL on STN
AN     2005:234233  USPATFULL
TI     PI-3 kinase inhibitor prodrugs
IN     Garlich, Joseph R., Westfield, IN, UNITED STATES
       Durden, Donald L., Decatur, GA, UNITED STATES
       Patterson, Mary, Carmel, GA, UNITED STATES
       Su, Jingdong, Westfield, IN, UNITED STATES
       Suhr, Robert G., Greenfield, IN, UNITED STATES
PI     US 2005203173       A1   20050915
AI     US 2005-111201      A1   20050420 (11)
RLI    Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
PRAI   US 2003-460137P     20030403 (60)
DT     Utility
FS     APPLICATION
LREP   HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE
```

200, FALLS CHURCH, VA, 22042-2924, US
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 13 USPATFULL on STN
AN 2005:215483 USPATFULL
TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
IN Bridon, Dominique P., Ville Mont-Royal, CANADA
Ezrin, Alan M., Moraga, CA, UNITED STATES
Milner, Peter G., Los Altos, CA, UNITED STATES
Holmes, Darren L., Montreal, CANADA
Thibaudeau, Karen, Montreal, CANADA
PA ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 2005187159 A1 20050825
AI US 2005-66697 A1 20050225 (11)
RLI Continuation of Ser. No. US 2000-657276, filed on 7 Sep 2000, GRANTED, Pat. No. US 6887470
PRAI US 1999-153406P 19990910 (60)
US 1999-159783P 19991015 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN FRANCISCO, CA, 94105-2482, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1-26
DRWN No Drawings
LN.CNT 5233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 13 USPATFULL on STN
AN 2005:107237 USPATFULL
TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
IN Bridon, Dominique P., Outremont, CANADA
Ezrin, Alan M., Moraga, CA, UNITED STATES
Milner, Peter G., Los Altos Hills, CA, UNITED STATES
Holmes, Darren L., Montreal, CANADA
Thibaudeau, Karen, Montreal, CANADA
PA Conjuchem, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6887470 B1 20050503
AI US 2000-657276 20000907 (9)
PRAI US 1999-159783P 19991015 (60)
US 1999-153406P 19990910 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Snedden, Sheridan
LREP Morrison & Foerster LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 13 USPATFULL on STN
AN 2005:105793 USPATFULL
TI Therapy via targeted delivery of nanoscale particles
IN Ivkov, Robert, Marblehead, MA, UNITED STATES
Daum, Wolfgang, Groton, MA, UNITED STATES
Foreman, Allan, Epping, NH, UNITED STATES
Gwost, Douglas, Shoreview, MN, UNITED STATES
PA Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)
PI US 2005090732 A1 20050428
AI US 2003-696399 A1 20031028 (10)
DT Utility
FS APPLICATION
LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET, PITTSBURGH, PA, 15219, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2898
AB Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

L6 ANSWER 8 OF 13 USPATFULL on STN
AN 2005:26381 USPATFULL
TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
IN Bridon, Dominique P., Outremont, CANADA

Ezrin, Alan M., Moraga, CA, United States
Milner, Peter G., Los Altos Hills, CA, United States
Holmes, Darren L., Montreal, CANADA
Thibaudeau, Karen, Montreal, CANADA
PA ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6849714 B1 20050201
WO 2000069900 20001123
AI US 2000-623548 20000905 (9)
WO 2000-US13576 20000517
20000905 PCT 371 date
PRAI US 1999-134406P 19990517 (60)
US 1999-153406P 19990910 (60)
US 1999-159783P 19991015 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Desai, Anand
LREP Morrison & Foerster LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 13 USPATFULL on STN
AN 2004:307955 USPATFULL
TI PI-3 kinase inhibitor prodrugs
IN Garlich, Joseph R., Westfield, IN, UNITED STATES
Durden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2004242631 A1 20041202
US 6949537 B2 20050927
AI US 2004-818145 A1 20040405 (10)
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34, 1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 13 USPATFULL on STN
AN 2004:197463 USPATFULL
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES
Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES
Dyakonov, Tatyana A., Durham, NC, UNITED STATES
PI US 2004152769 A1 20040805
AI US 2003-703647 A1 20031107 (10)
PRAI US 2002-424796P 20021109 (60)
US 2003-483676P 20030630 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR', and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thioimide, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonimide group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated form the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intraveneous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 13 USPATFULL on STN
AN 2004:23553 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
Rehlaender, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Bovet, Li Li, Chapel Hill, NC, UNITED STATES
PI US 2004017387 A1 20040129
US 7030082 B2 20060418
AI US 2003-382069 A1 20030305 (10)
RLI Continuation-in-part of Ser. No. US 2002-235281, filed on 5 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-235284, filed on 5 Sep 2002, PENDING
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also

provided, as well as methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 13 USPATFULL on STN
AN 2003:306886 USPATFULL
TI Peptides for recognition and targeting of GLIAL cell tumors
IN Samoylova, Tatiana I., Auburn, AL, UNITED STATES
Petrenko, Valery A., Auburn, AL, UNITED STATES
Cox, Nancy R., Auburn, AL, UNITED STATES
Morrison, Nancy E., Auburn, AL, UNITED STATES
Baker, Henry J., Auburn, AL, UNITED STATES
Globa, Ludmila P., Auburn, AL, UNITED STATES
PA Auburn University (U.S. corporation)
PI US 2003216322 A1 20031120
AI US 2003-357929 A1 20030204 (10)
PRAI US 2002-354118P 20020204 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 13 USPATFULL on STN
AN 2003:100060 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Li Li, Bovet, Chapel Hill, NC, UNITED STATES
PI US 2003069170 A1 20030410
US 6770625 B2 20040803
AI US 2002-235284 A1 20020905 (10)
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 130
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 3615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

SEA CHLOROTOXIN
---
3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHABS
3 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISSABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESBIOBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMSDRUGNEWS
5 FILE IMSRESEARCH
13 FILE LIFESCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PROMT
38 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPATFULL
7 FILE USPAT2
11 FILE WPIDS
11 FILE WPINDEX

L1 QUE CHLOROTOXIN

SEA L1 AND CHEMOTHER?
---
1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE ESBIOBASE
1 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH
1 FILE MEDLINE
2 FILE PHAR
1 FILE PHIN
11 FILE PROMT
3 FILE TOXCENTER
16 FILE USPATFULL
4 FILE USPAT2
2 FILE WPIDS
2 FILE WPINDEX

L2 QUE L1 AND CHEMOTHER?

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOBASE, IFIPAT, MEDLINE, PROMT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09

JUN 2006

L3	174	S L2
L4	163	DUP REMO L3 (11 DUPLICATES REMOVED)
L5	9	S L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
L6	13	S L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGU
L7	13	S L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM
L8	7	S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANT
L9	6	S L5 AND L6 AND L7 AND L8